Ustekinumab
NHS Wales is tendering for supply of Ustekinumab, a biologic medicine used to treat inflammatory conditions. The contract runs to 2026.
- Closed9 March 2026
- Value£9.5m
- BuyerNHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
- CategoryHealth & medical
- RegionWales
You'll want to look if you are an authorised pharmaceutical wholesaler or manufacturer able to supply biologic medicines to NHS Wales
Might not suit a small firm
- the contract itself is a large one
Possible incumbent
Novartis supplied Transitional Drugs 4 in October 2025; Ustekinumab is a Janssen product, so Novartis may not be the incumbent for this specific medicine. Inferred from prior awards to this buyer, not confirmed.